key: cord-0759746-e79ox3f4
authors: Azim, Adnan; Pini, Laura; Khakwani, Zeeshan; Kumar, Santosh; Howarth, Peter
title: SARS-CoV2 infection in those on Mepolizumab therapy
date: 2021-01-13
journal: Ann Allergy Asthma Immunol
DOI: 10.1016/j.anai.2021.01.006
sha: b9f152b183e999968e5eafbfb1caec00fce80cb2
doc_id: 759746
cord_uid: e79ox3f4

nan

The information and cases presented in this case series have not previously been presented or published. , caused by the severe acute respiratory syndrome 2 coronavirus 2 (SARS-CoV-2) 1 , continues to cause morbidity and mortality across the world. 3 Expert recommendation is to continue biologic therapy unchanged in severe eosinophilic 4 asthma 2,3 but concern has been expressed as eosinopenia may be a risk factor for worse 5 disease outcomes 4, 5 . Here we report the outcomes of four patients from centres in the UK, 6 Italy and North America with COVID-19, whilst receiving treatment with mepolizumab, an 7 anti IL-5 monoclonal antibody, which reduces eosinophils to within the normal range 6 . 8 Case 1 is a 64 year old Caucasian man with a history of childhood onset asthma, atopy and 9 rhinitis, whose asthma control deteriorated in his mid-40s. Despite treatment with high 10 dose ICS/LABA, LTRA, macrolides and intranasal steroids, his disease remained poorly 11 controlled: ACQ6 3.1, regular exacerbations and significant airflow limitation (FEV1 44%) 12 with blood eosinophil counts >500 cells/μl. Mepolizumab was started in 2013 with 13 consequent reduction in eosinophil counts (200 cells/μl) and exacerbations ( and, in parallel to a reduction in blood eosinophils to 70 cells/μl saw improvement in his Comments from the Editors:

We are very grateful to the editor and reviewers for their positive review of our manuscript and their constructive feedback. I have addressed each point in turn. The additional information, comments and discussion points mean that our new manuscript slightly exceeds the word and reference limits for a letter, however, we believe the updated manuscript to be much stronger.

Comments from Reviewers: Reviewer 1: The authors present a case series of 4 patients who had been treated with mepolizumab and then contracted SARS-CoV-2 and recovered. Although there is no new novel mechanistic insight presented, or unusual diagnoses discussed, the information is still useful to the field given the concern regarding the safety of the use of certain biologics during the COVID-19 pandemic, and the potential antiviral role of eosinophils. I have minor suggestions to help improve the clarity and of the presentation and the grammatical flow of the writing, as well as several suggestions of additional references and background that may be helpful, but no major scientific concerns.

1. To put this case series in context, and to highlight the importance of this issue and the ongoing debate around the role of eosinophils in viral infections, it would be helpful to add a few additional sentences/references to the introductory paragraph for background. For example, on the one hand, eosinophils are thought to have antiviral properties, with several studies showing this (PMID: 27049514, PMID: 28283567, and others), and in fact, one human study showed that patients with mild asthma who were treated with mepolizumab and then challenged with rhinovirus showed a significant increase in their rhinovirus viral titers in the upper airway, supporting an antiviral role for eosinophils (PMID: 30192638) and suggesting that mepolizumab treatment could be a risk factor for worsened viral infections. However, patients with eosinophilic asthma have an increased risk for viral-induced asthma exacerbations, with higher sputum eosinophil counts and higher FeNO being risk factors for viral-induced exacerbations (PMID: 28390083), suggesting that patients with eosinophilic asthma actually have reduced antiviral capabilities. Apologies; we have tried to include an expansion of the discussion, as we agree that this is an important issue. However, the revision was sent back for exceeding the word and reference limit and so has had to be removed again. 2. One additional reference may be appropriate to include, which reviewed the medical records of 85 fatal cases of COVID-19 and noted that 81% of the patients had eosinophil counts below the normal range at the time of admission. PMID: 1 (June 2020). We have added this reference, as per your suggestion.

3. The final paragraph states that "At presentation with SARS-CoV-2, they demonstrated a further reduction in their eosinophil counts". However, Case #3 (66yo F) did not have eosinophil counts reported during her infection, and Case #1 (64yo M) didn't have pre-COVID-19 eosinophil counts reported while on mepolizumab, so we cannot fully conclude that these two patients had infectioninduced reductions in their eosinophil counts. Unless there is additional data available for these patients, it would be more accurate to say "At presentation with SARS-CoV-2, at least two of them had a further infection-induced reduction in their eosinophil counts." Agreed. Have changed as per your suggestion.

4. There are many acronyms used (and some only used once) that are never defined. These should be spelled out at the first usage for clarity. We have included an abbreviation list with the manuscript as per the suggestion by Reviewer 2.

5. The names of generic medications should not be capitalized. Thank you.

6. The first opening statement of each case presentation is not a complete sentence, which is confusing to read. These should either be adjusted to be full sentences, or changed to read as a title statement, with headers of Case #1, Case #2, etc. Apologies for this poor grammatical oversight -we have changed this. 7. Some of the cases include the location/hospital at which the patient was seen and some do not. If this is relevant information, please include it for all 4 cases, with the additional general information of the city/country of the facility. If it is not relevant information then it could be deleted for all cases. Alternatively, in the introductory paragraph, the final sentence could read "Here we report the outcomes of four patients from four separate clinics, who developed COVID-19 whilst receiving treatment with mepolizumab, an anti-IL-5 monoclonal antibody, which reduces eosinophils to within the normal range". Agreed. Have changed as per your suggestion.

8. Line 40. Please describe what is meant by "biomass heating". It is difficult to expand on this with the limited word count -we believe that interested readers with a background in airways disease will be familiar with this term. However, we have changed the wording to be clearer: "using" biomass heating. 2) In line 4, when discussing reference number 4, the authors state that ".....eosinopenia has been identified as a risk factor.....". I feel that this wording is a bit too strong given the reference and its findings. Suggest to change to either "....eosinopenia has been associated with worse disease outcomes" or "....eosinopenia may be a risk factor for worse disease outcomes.". Thank you -have changed the wording to say eosinopenia may be a risk factor for worse disease outcomes Coronavirus disease 2019 (COVID-19) , caused by the severe acute respiratory syndrome 1 coronavirus 2 (SARS-CoV-2) 1 , continues to cause morbidity and mortality across the world. 2 Expert recommendation is to continue biologic therapy unchanged in severe eosinophilic 3 asthma 2,3 but concern has been expressed as eosinopenia may be a risk factor for worse 4 disease outcomes 4 . Here we report the outcomes of four patients from centres in the UK, 5 Italy and North America with COVID-19, whilst receiving treatment with mepolizumab, an 6 anti IL-5 monoclonal antibody, which reduces eosinophils to within the normal range 5 . 7 Case 1 is a 64 year old Caucasian man with a history of childhood onset asthma, atopy and 8 rhinitis, whose asthma control deteriorated in his mid-40s. Despite treatment with high 

A Novel Coronavirus from Patients with Pneumonia in China

ARIA-EAACI statement on asthma and COVID-19

Luxemburgische Gesellschaft fur Allergologie und Immunologie (LGAI)(E), Osterreichische Gesellschaft fur Pneumologie (OGP)(F) in co-operation with the German, Austrian, and Swiss ARIA groups(G), and the European Academy of

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan

Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan. A Retrospective Observational Study

Blood eosinophil count in the general population: typical values and potential confounders

Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19 patients in fever clinic: A retrospective case-control study

Eosinophil responses during COVID-19 infections and coronavirus vaccination

COVID-19 Autopsies

Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study